SCHEDULE 13G/A: BlackRock Discloses 6.3% Passive Stake in INOVIO PHARMACEUTICALS INC
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.3% beneficial ownership stake in INOVIO PHARMACEUTICALS INC as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,318,480 shares of Common Stock in INOVIO PHARMACEUTICALS INC.
- This ownership represents 6.3% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 2,277,782 shares and sole dispositive power over 2,318,480 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous filing regarding BlackRock's ownership.
- BlackRock certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial news about the issuer, thus a neutral sentiment score is appropriate.
Positives
- The disclosure of a significant stake by a major institutional investor like BlackRock, Inc. can be viewed as a vote of confidence in INOVIO PHARMACEUTICALS INC.
- The holding is passive, indicating it is for investment purposes rather than an attempt to influence or change control of the company.
Future Outlook
The document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding INOVIO PHARMACEUTICALS INC's future performance or outlook.
Management Comments
- BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure by a large institutional asset manager, BlackRock, Inc., indicating its passive investment in INOVIO PHARMACEUTICALS INC. It reflects BlackRock's portfolio management activities rather than a specific strategic move related to broader pharmaceutical industry trends or competitors.
Comparison to Industry Standards
- As a Schedule 13G filing, this document primarily reports beneficial ownership and does not provide financial or operational results for comparison to industry standards or specific comparable companies or projects. It is a standard regulatory disclosure of a passive investment stake.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can influence investor perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the current one. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting date for ownership). |
| 2025-04-17 | Date the Schedule 13G was signed by BlackRock, Inc. |
Keywords
BlackRock, INOVIO PHARMACEUTICALS, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.